Background-Our previous studies have shown that the in vitro cytotoxicity of gemcitabine and SN-38, the active metabolite of irinotecan (CPT-11), is synergistic in human tumor cell lines.
Background
Gemcitabine (2',2'-difiuoro-2'-deoxycytidine) is a cytidine analog with unique activity against solid tumors as reviewed elsewhere [1, 2] , After entering target cells on a concentrative nucleoside transporter cNTl [3] , gemcitabine is sequentially phosphorylated by deoxycytidine kinase, deoxycytidylate kinase and nucleoside diphosphate kinase to yield mono-, di-and triphosphate derivatives [4] [5] [6] . In contrast to gemcitabine, which is cleared from the circulation with a half-life of eight minutes, these intracellular metabolites persist for extended periods of time [4, 7] , Gemcitabine diphosphate inhibits ribonucleotide reductase, thereby causing a decrease in dCTP and other deoxyribonucleotides [5, 6, 8] . Gemcitabine triphosphate competes with dCTP for incorporation into DNA. This latter effect contributes to the ability of gemcitabine to activate the apoptotic process [9] , In addition, gemcitabine may also act by blocking RNA synthesis [10] , providing a potential explanation for the cytotoxicity of this agent in noncycling cells.
CPT-11 is a camptothecin derivative that also has broad spectrum antitumor activity as reviewed elsewhere [11, 12] . Upon intravenous administration, CPT-11 is deesterified to its active metabolite, SN-38 [13] . SN-38 in turn affects the action of the nuclear enzyme topoisomerase I. Topoisomerase I binds to supercoiled DNA, introduces a nick in one strand, allows controlled rotation of the intact strand and reseals the nick [14] [15] [16] [17] . SN-38 binds covalently to the topoisomerase I-DNA complex and inhibits the religation step [15, 16, 18] , trapping topoisomerase I on the DNA. When advancing replication forks interact with the trapped topoisomerase I-DNA complexes, irreparable DNA double-strand breaks result [15] [16] [17] , Because gemcitabine and CPT-11 have activity against a number of the same neoplasms, there is considerable interest in combining them. One commonly recommended dose and schedule of CPT-11 is 125 mg/m 2 weekly for four weeks with a two-week rest. The standard dose and schedule of gemcitabine is 1000 mg/m 2 weekly for three weeks with a one week rest. The optimal manner for combining these treatments is not currently known.
Previous studies in tissue culture have demonstrated that the cytotoxic effects of gemcitabine and CPT-11 are synergistic [19] . Based on these results, we have performed a phase I trial of gemcitabine + CPT-11 administered on days 1, 8, 15 and 22 of a six-week cycle. The goals of this trial were to determine 1) the maximal tolerated dose (MTD) of gemcitabine and CPT-11 on this schedule, 2) identify the dose limiting toxicity of the combination, and 3) seek preliminary evidence of antitumor activity.
Patients and methods

Patient selection
Patients who had solid tumors that were refractory to standard chemotherapy or for whom no effective alternative therapy existed were eligible for entry into this trial. The patients had Eastern Cooperative Oncology Group performance scores of < 2 and life expectancies of > 12 weeks. The inclusion criteria included' absolute neutrophil count of ^ 1500/mm 3 , bilirubin ^ 1.5 mg/dl, AST and alkaline phosphatase levels < 3 times the institutional upper limits of normal, creatinine $2.0 mg/dl, and negative pregnancy test for women of childbearing potential. Exclusion criteria included: chemotherapy, radiotherapy, or immunotherapy within four weeks of registration; radiation to >25% of the bone marrow; pregnancy or lactation; uncontrolled infections; chronic debilitating diseases; chronic debilitating diseases; New York Heart Association class 3 or 4 heart disease; or central nervous system metastases.
Pretreatment evaluation and follow-up studies A history and physical exam were performed prior to registration and before each subsequent course of chemotherapy. Studies performed at the time of registration included a CBC; measurement of serum AST, alkaline phosphatase, total and direct bilirubin, calcium, creatinine, sodium, potassium, and glucose; and a chest X-ray. CBCs were repeated weekly; and chemistries were repeated prior to each subsequent cycle of therapy. Measurements of an indicator lesion were performed within 14 days of registration, prior to the second cycle of therapy and then prior to every other cycle of therapy.
Drug administration
Gemcitabine was supplied as a lyophilized powder in 200 mg and 1000 mg vials and stored at room temperature. It was reconstituted with normal saline to yield a concentration of 40 mg/ml and administered as an i v. infusion in 250 ml NS over 30 minutes. CPT-11 was supplied as single-dose vials containing 100 mg in 5 ml (20 mg/ml). The calculated dose was diluted in 500 ml of DjW and administered as an intravenous infusion over 90 minutes immediately after the gemcitabine infusion. Drugs were administered on days 1, 8, 15 and 22 of a planned six-week cycle Cycles of treatment were repeated every six weeks if patients met the criteria for retreatment.
Study design and toxicity criteria
Three patients were treated at each dose level and observed for a minimum of 6 weeks before new patients are treated. Doses were not escalated in any individual patient. Using the National Cancer Institute Common Toxicity Criteria (NCI-CTQ, dose-limiting toxicity (DLT) for this study was defined as any of the following: grade 4 neutropenia or thrombocytopema lasting >5 days: serum creatinine > 2 time baseline or upper limit of normal, whichever was less; grade 4 nausea and vomiting despite maximal antiemetic treatment, grade 4 diarrhea in spite of intensive loperamide therapy; > grade 3 other nonhematological toxicity; failure to complete at least three of the planned four infusions per cycle; or failure to recover to $ grade 1 toxicity by day 43.
If DLT was seen in one of three patients treated at a given dose level, three additional patients were entered at the same dose level. If potentially DLT was not seen in any of the three additional patients, doses were escalated If DLT was seen in one or more of the three additional patients (i.e , two or more of the six patients entered at that dose level), the maximum tolerated dose (MTD) was considered to have been exceeded, further accrual at that dose level ceased and all further accrual occurred at the preceding dose to more fully assess the toxicities associated with the MTD. If a patient failed to complete the initial course of therapy (defined as drug administration and 2 weeks observation) for reasons other than toxicity, the patient was regarded as treatment intolerant and was replaced with an additional patient who was treated at the same dose level However, all toxicity information was utilized in the analysis. For patients who developed DLT a dose reduction schema allowed retreatment at one of the prior dose levels.
Response to therapy with gemcitabine and CPT-11 was defined as CR, PR, minor response, stable, or PROG A CR was defined as total disappearance of all evidence of tumor. A PR was defined asa ? 50% reduction in the sum of the products of the largest perpendicular diameters of the indicator lesion(s) chosen prior to therapy. A minor response was defined as definite decrease in the size of an evaluable lesion not meeting the criteria for a CR or PR. A PROG was defined as >25% increase in the bideminsional measurements of a tumor after a cycle of therapy or the appearance of new lesions. Patients were removed from treatment if they had a significant clinical deterioration that could not be attributed to treatment or other medical conditions
Statistical considerations
The primary endpoint for this single-arm phase I trial was the MTD for the combination of gemcitabine and CPT-11 given weekly for four weeks followed by a two week rest period. The Mayo Cancer Center Statistics Unit has constructed a standard set of analytic algorithms for evaluating the prescribed outcome measures and producing routine analysis in phase I trials [20] . This system incorporates automated data entry and error checking, continual updates of clinical data obtained for patients on study, summary reports and graphical representations on toxicity and efficacy results for each phase I study. Descriptive statistics formed the primary basis of analysis using the data from this system
Results
Twenty-four patients received a total of fifty cycles of therapy through five dose levels ( Table 1) . The characteristics of the patients enrolled in this study are shown in Table 2 . The patients had a wide range of cancers. Twenty-two (92%) had received prior chemotherapy, and eleven (46%) had received prior radiotherapy. All but one of these patients had an ECOG performance status of 0 or 1.
This group of patients received a median of two cycles per patient (range 1 6). All patients were evaluable for Table 2 . Characteristics of the 24 patients enrolled in the phase I trial of gemcitabine and CPT-11.
Characteristic
Number of patients • toxicity. One patient at dose level 1 died of neutropenic sepsis prior to completing the first cycle of therapy and was not evaluable for response. This patient had been previously treated with both radiation and chemotherapy for nasopharyngeal carcinoma. Sepsis developed after the day 14 treatment. DLT occurred in two out of six patients at dose level 4. At this dose level, two patients completed only two out of four weeks of treatment and one completed three out of four weeks of treatment. Of the remaining three patients treated at dose level 4, one patient required a reduction in the dose of CPT-11 for weeks 2-4.
At the MTD, consisting of gemcitabine 1000 mg/m 2 and CPT-11 100 mg/m 2 (dose level 3), one of six patients completed two out of four weeks of treatment and three others completed three out of four weeks. Of the remaining two patients, one required a dose reduction in order to complete all four weeks of treatment. Toxicities accounting for missed weeks of treatment or dose reductions at dose level 3 included hematologic toxicity (neutropenia, thrombocytopenia) in four patients and diarrhea in one patient. 
Hematologic toxicities
All toxicities associated with administration of gemcitabine combined with CPT-11 are summarized in Table 3 according to the NCI-CTC grading criteria. The most common hematologic side effects were leukopenia, neutropenia, and thrombocytopenia. As indicated above, one patient developed neutropenic sepsis after completing two weeks of treatment at dose level 1 and died as a complication of this infection. No other episodes of neutropenic sepsis occurred. Grade 3^4 neutropenia occurred in 35% of patients with the first cycle of therapy. At the MTD two patients had grade 3 neutropenia of 15 days duration or less and 2 patients had grade 2 neutropenia of 7 days duration. Grade 3-4 thrombocytopenia occurred in 17% of patients, including two patients with grade 4 thrombocytopenia at the MTD.
Non-hematologic toxicities
Diarrhea was the most common non-hematologic toxicity. Grade 3 diarrhea occurred in one patient at dose level 2 and one patient at dose level 4. Grade 1 or 2 diarrhea occurred at all dose levels and was observed in 43% of patients. At the MTD three patients developed grade 1 diarrhea and one patient developed grade 4 diarrhea. Grade 1-2 anorexia was reported in 12 patients and grade 1-2 alopecia in 9 patients. Other mild to moderate non-hematologic toxicities included fatigue, nausea, vomiting, and weight loss are shown in Table 3 . One patient reported minor body aches.
Tumor responses
One patient with transitional cell carcinoma of the kidney had a partial response sustained for six cycles of therapy. Six additional patients had minor responses or stable disease for at least two cycles of therapy (two gastroesophageal junction, tonsil, larynx, cecum, neuroendocrine of unknown primary).
Discussion
Gemcitabine and CPT-11 individually have broad-spectrum activity against a range of solid tumors, including cancers of the colon, breast, pancreas, lung, and bladder [12, 21, 22] . In addition, preclinical studies have demonstrated that treatment of neoplastic cells in vitro with SN-38 and gemcitabine results in greater than additive cytotoxic effects [19] . Accordingly, we have performed a phase I trial in which these agents were administered in combination.
One current schedule for administration of CPT-11 involves weekly administration for four out of every six weeks. In the present trial, both CPT-11 and gemcitabine were administered using this schedule. With this schedule, the MTD of the combination was determined to be gemcitabine 1000 mg/m 2 and CPT-11 100 mg/m 2 on days 1, 8, 15 and 22 of each 42-day cycle. The DLTat the next higher dose level was determined to be grade 4 hematologic toxicity resulting in two of six patients missing at least two of the planned four weeks of treatment. At the MTD one patient missed two weeks of treatment and three patients missed one week of treatment, primarily due to hematologic toxicity. One grade 4 diarrhea occurred at the MTD. In the entire group of patients, diarrhea was the only severe (grade 3, 2 patients) or life threatening (grade 4, 1 patient) non-hematologic toxicity.
In another phase I trial of the combination of gemcitabine and CPT-11, treatment was given on days 1 and 8 of a three-week cycle [23] . In this trial a fixed dose of gemcitabine 1000 mg/m 2 was combined with increasing doses of CPT-11. The MTD of CPT-11 was determined to be 100 mg/m 2 . Grade 4 diarrhea became dose limiting at 115 mg/m 2 . The three-week schedule was otherwise well tolerated. As with our schedule, there were several patients that were unable to receive all of the planned doses of therapy due to hematologic toxicity. At the MTD, one of five patients was unable to receive day 8 therapy as a result of grade 3 thrombocytopenia. This compares to three of six patients in our study who were unable to receive either day 15 or 22 of therapy due to toxicity and one patient who was unable to receive days 15 and 22 of therapy. For most of these patients, the missed days of treatment were due to hematologic toxicity. Indeed, the dose limiting toxicity of most multiday regimens including gemcitabine or CPT-11 has been myelosuppression [24] [25] [26] . Further experience with the weekly times 4 schedule used in this study is needed to determine if more treatment can be given compared to the weekly x 2 schedule.
One partial response was seen in a patient with transitional cell carcinoma of the kidney maintained over six cycles of therapy. With the potential activity of this combination, phase II studies appear to be indicated.
